Exjade (deferasirox) 500 mg dispersible tablets, 28 tablets — original (Novartis, Switzerland) Exjade (deferasirox) Targeted cancer therapy. Delivery from Europe within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415.

Indications

Treatment of chronic iron overload due to multiple blood transfusions (? 7 mL/kg/month of packed red blood cells) in patients with beta-thalassemia major aged 6 years and older.

Exijade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

• in patients with beta-thalassemia major with iron overload due to frequent blood transfusions (? 7 ml/kg/month of packed red blood cells) from 2 to 5 years of age;
• in patients with beta-thalassemia major with iron overload due to infrequent blood transfusions (
• in patients with other anemia from 2 years of age.
• Exijade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassemia syndromes from 10 years of age.